<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 10, 1997
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
NEW JERSEY 1-1-432 22-2429994
---------------------- ---------------- ---------------
(State or other (Commission (IRS Employer
jurisdiction of File Number Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced that David S.
Tierney, M.D., formerly of Elan Pharmaceutical Research Corporation, has
joined Roberts as Senior Vice President, Medical and Regulatory Affairs.
In this newly created position, Dr. Tierney will assume overall
responsibility for the drug development program at Roberts which, in recent
months, has been significantly expanded with the addition of compounds licensed
from Lilly and Pfizer that address potentially large markets.
Before joining Roberts, Dr. Tierney held senior positions with Elan
Pharmaceutical Research where his responsibilities included global clinical
development of new compounds in several different therapeutic categories. Most
recently he served Elan Pharmaceutical Research as Head of Worldwide Clinical
Research and prior to that as Director of Medical Affairs. Dr. Tierney is a
graduate of the Medical School of the Royal College of Surgeons, Dublin,
Ireland.
The Company commented that Dr. Tierney possesses an abundance of
experience in pharmaceutical product development and his background and
experiences should strongly augment Roberts existing staff of professionals and
the Company's commitment to bringing new products through development into the
market.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: April 11, 1997 By: /s/ Anthony A. Rascio
---------------------
Anthony A. Rascio
Vice President
